ROBOSENSE
RoboSense LiDAR , the leading smart LiDAR sensor provider, announced it will be exhibiting its latest cutting-edge LiDAR solutions at the Consumer Electronics Show (CES) on January 5 - 8 , 2022, starring RS-LiDAR M1 (M1), the world's first mass-produced automotive grade MEMS solid-state LiDAR. M1 will be joined at the stand by RS-Helios, the newest-generation bespoke LiDAR. RoboSense invites CES 2022 attendees to the West Hall, Tech East , Booth #6861, in Las Vegas, USA .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005289/en/
RoboSense is currently the only company in the world to have achieved mass-produced delivery of front-loading smart solid-state LiDAR. Looking ahead, RoboSense is sustainably empowered for the advent of the mass-produced LiDAR era with M1. Throughout 2021, RoboSense earned a large number of pre-installed fixed-point project orders from auto companies around the world, including the GAC Aion, WM Motor, ZEEKR (a Geely holding company), Lotus Cars, and Inceptio Technology.
M1’s extra small size makes it exceptionally convenient for front loading in mass production models. It is equipped with a unique smart "GAZE" function, which can dynamically and intelligently switch between far-field and near-field perception, substantially leveling up the performance of smart driving systems in different scenes.
This year, M1 has also been recognized for its innovation excellence and contribution to advancing smart mobility, winning a prestigious 2021 Automotive News PACE Award and a 2021 CLEPA Award from the European Association of Automotive Suppliers.
RoboSense is garnering worldwide recognition for its complete innovative portfolio in LiDAR and AI perception solutions. This is proven by its representing 10% of the global automotive pre-installed market, which ranks 1st in China and 2nd worldwide .
Taking the global stage at CES 2022, RoboSense will exhibit the latest LiDAR products and proven LiDAR technologies, including but not limited:
- RS-LiDAR-M1 , SOP version automotive-grade solid-state LiDAR
- RS-HELIOS-5515 , super-wide vertical FoV LiDAR
- RS-Bpearl , industrial unique design blind spot LiDAR
- RS-Ruby , upgraded 128-beam mechanical LiDAR
- RS-Ruby Lite , upgraded 80-beam mechanical LiDAR
- RS-Reference , full-stalk ground truth reference system
With RoboSense’s CES 2022 exhibition around the corner, all attendees - including clients, journalists, analysts, and industry partners - are welcome to visit RoboSense’s booth for detailed solution introductions and live product demonstrations. To schedule a meeting with RoboSense LiDAR and get exclusive access to news, or collaborate on upcoming stories and trends, please reach out to grace.ye@robosense.cn directly. An exciting world of smart mobility awaits.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005289/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom